A carregar...
Mechanism-based drug combinations with the DNA-strand-breaking nucleoside analog, CNDAC
CNDAC (2’-C-cyano-2’-deoxy-1-β-D-arabino-pentofuranosyl-cytosine, DFP10917) and its orally bioavailable prodrug, sapacitabine, are undergoing clinical trials for hematological malignancies and solid tumors. The unique action mechanism of inducing DNA strand breaks distinguishes CNDAC from other deox...
Na minha lista:
| Publicado no: | Mol Cancer Ther |
|---|---|
| Main Authors: | , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
2016
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5050117/ https://ncbi.nlm.nih.gov/pubmed/27474148 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1535-7163.MCT-15-0801 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|